ELEDON PHARMACEUTICALS INC
NASDAQ: ELDN (Eledon Pharmaceuticals, Inc.)
Last update: 1 hour ago2.78
0.00 (0.00%)
| Previous Close | 2.78 |
| Volume | 632,515 |
| Price / Earnings (Forward) | 5.39 |
| Price / Book | 6.84 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.040 |
| Total Debt/Equity (MRQ) | 0.77% |
| Current Ratio (MRQ) | 13.90 |
| Operating Cash Flow (TTM) | -54.59 M |
| Levered Free Cash Flow (TTM) | -26.72 M |
| Return on Assets (TTM) | -40.10% |
| Return on Equity (TTM) | -38.15% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Eledon Pharmaceuticals, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.67 |
|
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.40% |
| % Held by Institutions | 68.39% |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |